Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells

Experimental Hematology

Volumn 36, Issue 2, 2008, Pages 149-157

  Khan, Rasheed ^a   Schmidt Mende, Jan ^a   Karimi, Mohsen ^a   Gogvadze, Vladimir ^a   Hassan, Moustapha ^a   Ekström, Tomas J ^a   Zhivotovsky, Boris ^a   Hellström Lindberg, Eva ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; AZACITIDINE; CASPASE; CYTARABINE; DNA; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL STRAIN HL 60; CONTROLLED STUDY; DNA METHYLATION; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; T LYMPHOCYTE; WESTERN BLOTTING;

APOPTOSIS; AZACITIDINE; CASPASES; CYTOSOL; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; IONOPHORES; JURKAT CELLS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MONENSIN; MYELODYSPLASTIC SYNDROMES; MYELOID CELLS; ORGANOMETALLIC COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-BCL-2; TIME FACTORS;

EID: 38149088287     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.10.002     Document Type: Article

References (47)

1. Gryn J., Zeigler Z.R., Shadduck R.K., et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res 26 (2002) 893-897
2. Silverman L.R., Holland J.F., Weinberg R.S., et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 Suppl 1 (1993) 21-29
3. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002) 2429-2440
4. Kornblith A.B., Herndon II J.E., Silverman L.R., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20 (2002) 2441-2452
5. Notari R.E., and DeYoung J.L. Kinetics and mechanisms of degradation of the antileukemic agent 5-azacytidine in aqueous solutions. J Pharm Sci 64 (1975) 1148-1157
6. Kissinger L.D., and Stemm N.L. Determination of the antileukemia agents cytarabine and azacitidine and their respective degradation products by high-performance liquid chromatography. J Chromatogr 353 (1986) 309-318
7. Rustum A.M., and Hoffman N.E. High-performance liquid chromatographic determination of 5-azacytidine in plasma. J Chromatogr 421 (1987) 387-391
8. Rudek M.A., Zhao M., He P., et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23 (2005) 3906-3911
9. Khan R., Aggerholm A., Hokland P., Hassan M., and Hellstrom-Lindberg E. A pharmacodynamic study of 5-azacytidine in the P39 cell line. Exp Hematol 34 (2006) 35-43
10. Karimi M., Johansson S., and Ekstrom T.J. Using LUMA: a luminometric based assay for global DNA-methylation. Epigenetics 1 (2006) 45-48
11. Karimi M., Johansson S., Stach D., et al. LUMA (LUminometric Methylation Assay)-a high throughput method to the analysis of genomic DNA methylation. Exp Cell Res 312 (2006) 1989-1995
12. Karimi M., Johansson S., and Ekström T. Using LUMA: a luminometric based assay for global DNA-methylation. Epigenetics 1 (2006) 45-48
13. Stenvinkel P., Karimi M., Johansson S., et al. Impact of inflammation on epigenetic DNA methylation-a novel risk factor for cardiovascular disease?. J Intern Med 261 (2007) 488-499
14. Gardner C.R. Anticancer drug development based on modulation of the Bcl-2 family core apoptosis mechanism. Expert Rev Anticancer Ther 4 (2004) 1157-1177
15. Doyle B.T., O'Neill A.J., Fitzpatrick J.M., and Watson R.W. Differentiation-induced HL-60 cell apoptosis: a mechanism independent of mitochondrial disruption?. Apoptosis 9 (2004) 345-352
16. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
17. Zhivotovsky B., and Orrenius S. Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 331 (2005) 859-867
18. Pieper A.A., Verma A., Zhang J., and Snyder S.H. Poly (ADP-ribose) polymerase, nitric oxide and cell death. Trends Pharmacol Sci 20 (1999) 171-181
19. Wang H., Yu S.W., Koh D.W., et al. Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J Neurosci 24 (2004) 10963-10973
20. Komjati K., Mabley J.G., Virag L., Southan G.J., Salzman A.L., and Szabo C. Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke. Int J Mol Med 13 (2004) 373-382
21. Yu S.W., Wang H., Dawson T.M., and Dawson V.L. Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity. Neurobiol Dis 14 (2003) 303-317
22. Ahmad K.A., Clement M.V., Hanif I.M., and Pervaiz S. Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 64 (2004) 1452-1459
23. Clement M.V., Hirpara J.L., and Pervaiz S. Decrease in intracellular superoxide sensitizes Bcl-2-overexpressing tumor cells to receptor and drug-induced apoptosis independent of the mitochondria. Cell Death Differ 10 (2003) 1273-1285
24. Pervaiz S., Cao J., Chao O.S., Chin Y.Y., and Clement M.V. Activation of the RacGTPase inhibits apoptosis in human tumor cells. Oncogene 20 (2001) 6263-6268
25. Pervaiz S., Ramalingam J.K., Hirpara J.L., and Clement M.V. Superoxide anion inhibits drug-induced tumor cell death. FEBS Lett 459 (1999) 343-348
26. Rosato R.R., Almenara J.A., and Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63 (2003) 3637-3645
27. Braun T., Carvalho G., Coquelle A., et al. NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 107 (2006) 1156-1165
28. Schmidt-Mende J., Gogvadze V., Hellstrom-Lindberg E., and Zhivotovsky B. Early mitochondrial alterations in ATRA-induced cell death. Cell Death Differ 13 (2006) 119-128
29. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
30. Robertson J.D., Enoksson M., Suomela M., Zhivotovsky B., and Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J Biol Chem 277 (2002) 29803-29809
31. Bouchard V.J., Rouleau M., and Poirier G.G. PARP-1, a determinant of cell survival in response to DNA damage. Exp Hematol 31 (2003) 446-454
32. Murakami T., Li X., Gong J., Bhatia U., Traganos F., and Darzynkiewicz Z. Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res 55 (1995) 3093-3098
33. Kiziltepe T., Hideshima T., Catley L., et al. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther 6 (2007) 1718-1727
34. Morales-Ramirez P., Vallarino-Kelly T., and Cruz-Vallejo V.L. Mechanisms of DNA breaks induction in vivo by 5-azacytidine: paths of micronucleus induction by azaC. J Appl Toxicol (2007 Aug 8) [Epub ahead of print]
35. Mikita T., and Beardsley G.P. Functional consequences of the arabinosylcytosine structural lesion in DNA. Biochemistry 27 (1998) 4698-4705
36. Ciesielska E., Studzian K., Wasowska M., Oszczapowicz I., and Szmigiero L. Cytotoxicity, cellular uptake and DNA damage by daunorubicin and its new analogues with modified daunosamine moiety. Cell Biol Toxicol 21 (2005) 139-147
37. Jurisicova A., Lee H.J., D'Estaing S.G., Tilly J., and Perez G.I. Molecular requirements for doxorubicin-mediated death in murine oocytes. Cell Death Differ 13 (2006) 1466-1474
38. Kanno S., Shouji A., Hirata R., Asou K., and Ishikawa M. Effects of naringin on cytosine arabinoside (Ara-C)-induced cytotoxicity and apoptosis in P388 cells. Life Sci 75 (2004) 353-365
39. Hellstrom-Lindberg E., Robert K.H., Gahrton G., et al. A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Br J Haematol 81 (1992) 503-511
40. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24 (2006) 3895-3903
41. Wijermans P., Lubbert M., Verhoef G., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18 (2000) 956-962
42. Berg T., Guo Y., Abdelkarim M., Fliegauf M., and Lubbert M. Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell lines. Leuk Res 31 (2007) 497-506
43. Reu F.J., Bae S.I., Cherkassky L., Leaman D.W., et al. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. J Clin Oncol 24 (2006) 3771-3779
44. Levine J.J., Stimson-Crider K.M., and Vertino P.M. Effects of methylation on expression of TMS1/ASC in human breast cancer cells. Oncogene 22 (2003) 3475-3488
45. Hopkins-Donaldson S., Bodmer J.L., Bourloud K.B., Brognara C.B., Tschopp J., and Gross N. Loss of caspase-8 expression in highly malignant human neuroblastoma cells correlates with resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 60 (2000) 4315-4319
46. Deng G., Nguyen A., Tanaka H., et al. Regional hypermethylation and global hypomethylation are associated with altered chromatin conformation and histone acetylation in colorectal cancer. Int J Cancer 118 (2006) 2999-3005
47. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 21 (2002) 5400-5413